ACTRN12614000799651招募中未知
Effect of glucagon-like peptide infusion on systemic and adipose tissue inflammation in obese people.
Associate Professor Patrick Manning0 个研究点目标入组 12 人开始时间: 2014年7月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Body mass index>30 kg/m2
排除标准
- •Diabetes, cigarette smoking, malignancies, cardiac and vascular diseases, uncontrolled hypertension, psychiatric disorders, previous significant abdominal surgery, medications which affect inflammation or glucose metabolism
研究者
相似试验
已完成
不适用
Effect of glucagon-like-peptide-1 (GLP-1) on left ventricular function during percutaneous coronary intervention (PCI)ISRCTN77442023Papworth Hospital NHS Foundation Trust (UK)40
进行中（未招募）
1 期
iraglutide to Short Bowel Syndrome, a cross-over studyShort bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytesrestricted oral/enteral nutrition to reduce intestinal lossesdisease-related hypophagialack of adaptive hyperphagiaaccelerated gastrointestinal transit timeMedDRA version: 19.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-000825-35-DKRigshospitalet Blegdamsvej16
已完成
1 期
The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.ACTRN12608000428369Royal Adelaide Hospital24
已完成
2 期
Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?Blood GlucoseType-2 DiabetesMetabolic and Endocrine - DiabetesACTRN12610000185066Adam Deane10
已完成
2 期
Exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in the critically ill.Blood GlucoseMetabolic and Endocrine - Other metabolic disordersACTRN12609000093280Adam Deane8